ZURICH, Jan. 30,
2025 /PRNewswire/ -- NLS Pharmaceutics
Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the
"Company"), a Swiss clinical-stage biopharmaceutical company
focused on developing innovative therapies for central nervous
system (CNS) disorders, is pleased to announce the submission of
three research abstracts to the 2025 Annual Meeting of the
American Society of Clinical Psychopharmacology (ASCP).
The ASCP Annual Meeting, taking place from May 27 to May 30, 2025, at the Fairmont
Scottsdale Princess in Scottsdale,
Arizona, is one of the world's leading conferences
dedicated to advancing research in neuropsychopharmacology. This
prestigious event provides a platform for cutting-edge research and
innovative therapeutic approaches in neuropsychiatric drug
development, precision psychiatry, and addiction medicine.
NLS Submitted Research Abstracts:
- Evaluating the Effects of Mazindol on Fentanyl Dependence in
Animal Models (Study KO-943)
This study explores the therapeutic potential of Mazindol
ER, a triple monoamine reuptake inhibitor with additional
activity on 5-HT1A, MOP, and OX2R receptors, for fentanyl
dependence. Preclinical data will demonstrate its ability to
mitigate reward-seeking behavior and withdrawal symptoms,
positioning it as a promising non-opioid alternative for managing
fentanyl addiction.
- Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary
Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy
This research presents promising preclinical findings
on AEX-41 and AEX-2, two novel dual
orexin receptor agonists (DOXA), in a mouse model of narcolepsy. In
preliminary conclusion, these compounds exhibit wake-promoting
properties without the adverse metabolic effects associated with
traditional stimulants, making them strong candidates for treating
narcolepsy and related hypersomnolence disorders.
- Comprehensive Multitarget Strategy for Managing
Diabetes-Associated Neurological and Sleep Disorders (DANS)
This study introduces an innovative pharmacological platform for
treating diabetes-related cognitive and sleep disorders. The
research integrates dual orexin receptor agonists
(DOXA), neuropeptide-based preconditioning, and metabolic
modulators to address the interplay between neuroinflammation,
β-cell dysfunction, and circadian rhythm disruption.
Advancing Clinical Research in
Neuropsychopharmacology
"NLS Pharmaceutics is honored to contribute to the 2025
ASCP Annual Meeting, one of the premier global platforms for
advancing clinical research in neuropsychopharmacology,"
said Dr. Eric Konofal, MD, PhD, Chief Scientific
Officer of NLS Pharmaceutics. "Our research spans innovative
therapeutic solutions such as Mazindol ER for fentanyl dependence,
dual orexin receptor agonists for narcolepsy, and a multitarget
approach to managing diabetes-related neurological and sleep
disorders. These abstracts reflect our commitment to addressing
critical unmet medical needs in addiction medicine, sleep
disorders, and cognitive health."
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage
biopharmaceutical company dedicated to the development of
groundbreaking therapies for rare and complex CNS disorders. The
Company collaborates with world-renowned scientists and
pharmaceutical partners to advance innovative treatments in areas
such as addiction medicine, sleep disorders, and cognitive
dysfunction. For more information,
visit www.nlspharma.com.
Forward-Looking Statements
This press release contains expressed or implied forward-looking
statements pursuant to U.S. Federal securities laws. For example,
NLS is using forward-looking statements when it discusses the
potential of Mazindol ER and the AEX-41 and AEX-2
compounds for the treatment of various conditions. These
forward-looking statements and their implications are based on the
current expectations of the management of NLS only and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. The following factors, among others,
could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; NLS may encounter delays or obstacles in
launching and/or successfully completing its clinical trials; NLS
products may not be approved by regulatory agencies, NLS technology
may not be validated as it progresses further and its methods may
not be accepted by the scientific community; NLS may be unable to
retain or attract key employees whose knowledge is essential to the
development of its products; unforeseen scientific difficulties may
develop with NLS' process; NLS' products may wind up being more
expensive than it anticipates; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; NLS patents may not be sufficient; NLS
products may harm recipients; changes in legislation may adversely
impact NLS; inability to timely develop and introduce new
technologies, products and applications; and loss of market share
and pressure on pricing resulting from competition, which could
cause the actual results or performance of NLS to differ materially
from those contemplated in such forward-looking statements. Except
as otherwise required by law, NLS undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting NLS is
contained under the heading "Risk Factors" in NLS annual report on
Form 20-F for the year ended December 31,
2023 filed with the Securities and Exchange Commission
(SEC), which is available on the SEC's website, www.sec.gov, and in
subsequent filings made by NLS with the SEC.
Contact:
Investor Relations Contact
InvestorRelations@nls-pharma.com
www.nlspharma.com
View original
content:https://www.prnewswire.com/news-releases/nls-pharmaceutics-announces-the-submission-of-three-research-abstracts-to-the-2025-ascp-annual-meeting-302364295.html
SOURCE NLS Pharmaceutics Ltd.